A University of Nottingham spin-out business is tipped as one to watch at a UK national awards ceremony.
Exonate, who are developing eye treatment for Wet Age-related Macular Degeneration, (Wet AMD) was named ‘One to Watch’ in the Best Investment in Life Sciences category at the UK Business Angels Association Investment Awards.
The award is aimed at businesses in the early stage to scale-up phase that are building high growth potential businesses.
Wet AMD is a leading cause of vision loss in people aged 60 years or older and affects more than 30 million people worldwide. If untreated, patients are likely to lose sight in the affected eye within 24 months of the onset of the disease.
Professor David Bates, Head of Cancer Biology Unit in the School of Medicine, is Chief Scientific Officer of Exonate.
School of Medicine
The University of Nottingham
D Floor, West Block, Queen's Medical Centre
Nottingham, NG7 2UH
telephone: +44 (0) 115 82 31135
Connect with the University of Nottingham through social media and our blogs.
Campus maps | More contact information | Jobs
Browser does not support script.